Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label elranatamab monotherapy in Japanese patients with relapsed/refractory multiple myeloma
jRCT2021210002Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of elranatamab in multiple myeloma (MM), sponsored by Pfizer. Primary endpoint: Number of participants with dose-limiting toxicity (DLT). Started Mar 2021; status: completed.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2021210002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210002.